Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
about
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.The evolving place of incretin-based therapies in type 2 diabetesExenatide once weekly: clinical outcomes and patient satisfaction.Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.Emerging treatment options for type 2 diabetesSaxagliptin for type 2 diabetesDapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes.Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus.Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs.Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptinDPP-4 inhibitors in clinical practice.Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.Saxagliptin for the treatment of type 2 diabetes mellitus: focus on recent studies.The importance of synthetic drugs for type 2 diabetes drug discovery.Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment.Pharmacokinetic, pharmacodynamic and clinical evaluation of saxagliptin in type 2 diabetes.Saxagliptin for the treatment of diabetes - a focus on safety.Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes.New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptinType 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors.Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis.A pharmacometric approach to quantify the impact of chronic kidney disease and hemodialysis on systemic drug exposure: application to saxagliptin.Efficacy and safety of saxagliptin in combination with metformin as initial therapy in Chinese patients with type 2 diabetes: Results from the START study, a multicentre, randomized, double-blind, active-controlled, phase 3 trial.Dapagliflozin/Saxagliptin Fixed-Dose Tablets: A New Sodium-Glucose Cotransporter 2 and Dipeptidyl Peptidase 4 Combination for the Treatment of Type 2 Diabetes.Saxagliptin add-on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin with or without metformin: Results from the SUPER study, a randomized, double-blind, placebo-controlled trial.DPP-4 inhibitors and heart failure: a potential role for pharmacogenomics.Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study.Anti-diabetic potential of selected Malaysian seaweeds
P2860
Q30249371-FEEEE022-3427-4075-8F6D-EFF102217353Q33866808-233DE891-D6D7-4B55-A471-3A4580BC52EBQ34144380-47627AB6-293B-4971-9106-0D7532191B26Q34239784-149D813B-E536-4588-A710-CC125FE34BD0Q34381281-1CD74948-9CAF-4F3F-8E39-B85DD590D450Q34620486-D62FA013-38E6-45CB-8E4D-CB4408128F0DQ35111555-F98D163B-6458-4C5A-8C0F-842DAF7C550AQ35411329-29961F58-D0E0-4275-A892-8D5AE0988E2BQ35497064-F8453C0E-4EFF-4EFA-8A82-6CAD4B8D70E9Q37468406-01475F6C-2BCC-42D9-B3EA-110E4B1CFAC6Q37638984-797C5C81-198E-4C91-91A4-9454B86850DBQ37735838-DD2DE028-6336-4543-92ED-8DE3C2AFB914Q37941683-B5602905-0C08-404B-8A2C-42F5C0CB62F0Q37963451-75049152-AEED-435F-A33A-6668385044BEQ38139508-4216B213-A7AB-47DE-B6BA-D4C76FD73C78Q38200670-FBB9697F-F3E3-4980-9716-F1ECF25CCECDQ38734181-8C28383A-339F-43EF-9666-5FE66074FEB3Q38753500-57C7548A-82BF-44AE-9CE4-C365A8B98790Q40054637-69E5FED5-B458-4158-AF2F-57F5344C0DE3Q42058426-4D9A310F-EC2E-4F9F-8FDD-1CBBF6B84B04Q42171281-338F9358-8A42-444A-8889-869C16C184D6Q45402744-2F9E2D37-4373-45D1-BFC5-80923A791DF6Q45826429-A2A10003-AD59-4D12-8BAB-86A2023B806CQ47768884-70AFE7DE-A942-4738-A568-B286B6E34230Q48015498-4E3A4C8D-44AA-4098-B1D9-2549BED92630Q48048810-7474EF97-7288-43A0-86F0-C824FD9366EDQ48229830-6D434E1F-2CF1-406A-B92B-AAC4948F62CBQ51367101-5546DBD8-C866-43C6-8B0C-090CE10477FAQ56940876-38D96A93-4ABF-4654-90EB-5E55A4BAEF97
P2860
Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
@en
Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
@nl
type
label
Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
@en
Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
@nl
prefLabel
Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
@en
Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
@nl
P2860
P1433
P1476
Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus
@en
P2093
Anthony H Barnett
Milan K Piya
P2860
P2888
P304
P356
10.1007/S12325-009-0014-9
P407
P577
2009-03-27T00:00:00Z